The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
